SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for the treatment of rare diseases with unmet medical needs. Its product pipeline includes treatments for conditions such as cutaneous T-cell lymphoma, plaque psoriasis, and oral mucositis, as well as biodefense vaccines like RiVax® to prevent ricin poisoning. The company operates through specialized programs funded by government grants and contracts, emphasizing its expertise in orphan drug development and public health solutions. Soligenix serves patients and healthcare providers in the biopharmaceutical sector, primarily in the United States.